Evidence map›Paper›PMID 41051941›Full record

ArticleThe Journal of general virology2025

Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.

Martina Pfranger, Nina Krause, Benedikt Asbach, Johannes Meier, George Carnell, Lara Scheer, Anja Kalender, David Brenner, Paul Tonks, Simon Frost and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of general virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Martina PfrangerInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Nina KrauseDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Benedikt AsbachInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Johannes MeierInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
George CarnellDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Lara ScheerInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Anja KalenderInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
David BrennerInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Paul TonksDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Simon FrostDIOSynVax Ltd™, Cambridge, UK.
Edward WrightSchool of Life Sciences, University of Sussex, Brighton, UK.
Ingo JordanProBioGen AG, Berlin, Germany.
Emma KennedyUK Health Security Agency (UK), Porton Down, Salisbury, UK.
Roger HewsonUK Health Security Agency (UK), Porton Down, Salisbury, UK.
Barbara BlacklawsDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Andrew ChanDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Srivatsan ParthasarathyDIOSynVax Ltd™, Cambridge, UK.
Stuart DowallUK Health Security Agency (UK), Porton Down, Salisbury, UK.
Miles CarrollPandemic Sciences Institute & Centre for Human Genetics, University of Oxford, Oxford, UK.
Volker SandigProBioGen AG, Berlin, Germany.
Sofiya FedosyukDIOSynVax Ltd™, Cambridge, UK.
Rebecca KinsleyDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Jonathan HeeneyDepartment of Veterinary Medicine, Lab of Viral Zoonotics, University of Cambridge, Cambridge, UK.
Ralf WagnerInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multivalent vaccine targeting high-consequence infectious diseases in Sub-Saharan Africa (SSA), which are linked to high mortality, morbidity and overlapping clinical manifestations, would significantly improve health security and economic stability in this region. Trivalent vector vaccines were devised to deliver digitally optimized versions of Orthoebolavirus, Orthomarburgvirus glycoproteins (GPs) and a Lassa mammarenavirus (LASV) nucleoprotein (NP) by a single Modified Vaccinia Ankara (MVA) known to protect against mpox virus (MPXV) along with a matched DNA vaccine. Three immunizations in mice and Hartley guinea pigs with MVA only or a DNA prime followed by two MVA administrations induced comparable levels of binding antibodies and LASV-specific T-cells, respectively. While DNA priming mitigated MVA-specific antibody responses, GP- and NP-specific antibodies developed already after a single MVA vaccination. Although a post-outbreak Ebola virus vaccine is available, outbreaks by other filoviruses, annual LASV epidemics and increased incidence of MPXV infections support the rationale for an MVA-based trivalent haemorrhagic fever vaccine for endemic and high-risk human populations in SSA.

Indexed as

Hemorrhagic Fevers, ViralImmunogenicity, VaccineLassa FeverLassa virusMarburgvirusSmallpox VaccineAnimalsAntibodies, ViralFemaleGuinea PigsMarburg Virus DiseaseMiceVaccines, DNAAntibodies, ViralSmallpox VaccineVaccines, DNAhaemorrhagic fever virusesModified Vaccinia Ankara (MVA)multivalent vaccine

Identifiers

PMID41051941
PMCPMC12500382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.